Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07560865 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

Name: First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma — clinical trial record (NCT07560865)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorMasonic Cancer Center, University of Minnesota

Started2026-04-23

View on ClinicalTrials.gov ↗

Masonic Cancer Center, University of Minnesota

58 trials monitored

See 2 trials at risk

Glioblastoma

666 trials monitored

See 45 trials at risk

Glioma

666 trials monitored

See 38 trials at risk

This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally

Trial Details

NCT Number	NCT07560865
Lead Sponsor	Masonic Cancer Center, University of Minnesota Collaborators: Fate Therapeutics
Conditions	Astrocytoma, Glioblastoma, Progressive Disease
Enrollment	9 participants
Start Date	2026-04-23
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-01